February 26, 2021
Business News

Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D

TOKYO & MUNICH & BASKING RIDGE, N.J.–()–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research & Development as of April 1, 2021. On that date, Dr. Junichi Koga will retire from the position, after a successful and industrious career, including more than 12 years at Daiichi Sankyo.

Dr. Takeshita joins Daiichi Sankyo from Kite Pharma, a Gilead Company, where he was Senior Vice President and Global Head of Development since 2019, and interim Head of Research. Ken is a highly experienced physician with deep experience in oncology and rare diseases. Prior to Kite, he served as Senior Vice President of Clinical Research at Sorrento…

Click here to view the original article.

Related Posts

You might also like ...

beaconsmind AG (Euronext: MLBMD) Announces the Hiring of Capital Markets Specialist Baader Bank to Evaluate Options for a Dual-listing on a German-speaking Stock Exchange
Bluegreen Vacations Corporation to Issue Financial Results for the Fourth Quarter and Year-End 2020 on March 1, 2021
Sanderson Farms to Participate in BofA Securities 2021 Consumer & Retail Technology Conference